APPG for Life Sciences Update
The APPG for Life Sciences has continued its activities to update and inform MPs and Peers on the work of our sector over the autumn The latest session focussed on the NICE Methods Review’s implications for patients and the life sciences sector.
The National Institute for Health and Care Excellence (NICE) is currently undertaking a crucial review of the methods it uses to determine whether new medicines can be offered to patients in the NHS. The review has major implications for the quality of care patients can expect to receive in the future, business investment in the UK and the research and development of future innovative treatments. BIVDA Board Member John Bagshaw presented on the impact of the review on medical devices and IVDs and the processes members may have to follow on its conclusion.
John highlighted that the UK IVD industry is limited by slow adoption of new technologies and by unhelpful procurement systems in a market dominated by the NHS which is often more conscious of cost than benefit. Innovation from UK academia needs access to global markets and an indigenous industry which can rapidly commercialise new technologies. NICE assessments need to recognise the potential benefits of IVDs in health care which can transform current practices and ensure there are incentives for their implementation in primary as well as secondary care.